Amcad Biomed (ROCO:4188) 5-Year Yield-on-Cost %: 0.00 (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4188 Amcad Biomed Corp ROCO:4188
50 GF Score
Price NT$14.15
GF Value NT$9.56
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amcad Biomed 5-Year Yield-on-Cost %?

Amcad Biomed ROCO:4188 -0.35% 50 5-Year Yield-on-Cost % is 0.00 as of Sep. 16, 2026. GuruFocus rates ROCO:4188 with a GF Score™ of 50/100 and a GF Value™ of NT$9.56 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 313 Medical Devices & Instruments companies, Amcad Biomed ranks worse than 319488.5% on this metric.

Amcad Biomed's yield on cost for the quarter that ended in Jun. 2026 was 0.00.


The historical rank and industry rank for Amcad Biomed's 5-Year Yield-on-Cost % or its related term are showing as below:



ROCO:4188's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.52
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Amcad Biomed  (ROCO:4188) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Amcad Biomed 5-Year Yield-on-Cost % Related Terms


ROCO:4188 vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison

For the Medical Devices subindustry, Amcad Biomed's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amcad Biomed 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Amcad Biomed's 5-Year Yield-on-Cost % falls into.


ROCO:4188
50GF Score
Amcad Biomed Corp ROCO:4188
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amcad Biomed 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Amcad Biomed is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Amcad Biomed (ROCO:4188) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 16, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Amcad Biomed and its competitors. According to the industry distribution chart, Amcad Biomed ranks #999999 out of 313 companies in the Medical Devices & Instruments industry.
Is Amcad Biomed's 5-Year Yield-on-Cost % too high?
Amcad Biomed's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Amcad Biomed ranks #999999 out of 313 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Amcad Biomed has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #999999 out of 313 companies for 5-Year Yield-on-Cost %. This places Amcad Biomed in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.52, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Amcad Biomed and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amcad Biomed's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$9.56, compared to a current price of NT$14.15 — trading 48% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Amcad Biomed's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amcad Biomed (ROCO:4188) Overvalued in 2026?

Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued. The current stock price of NT$14.15 is trading 48% above its estimated GF Value™ of NT$9.56. GuruFocus considers Amcad Biomed to be Significantly Overvalued.

Key valuation signals for ROCO:4188:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: NT$9.56 vs. price of NT$14.15 (48% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amcad Biomed Business Description

Address Fuxing N. Road, No. 167, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
50GF Score

Get the complete analysis for ROCO:4188

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$14.15
Price
NT$9.56
GF Value